Goldman Sachs Group Inc. Decreases Stake in CureVac N.V. $CVAC

Key Points

• Goldman Sachs Group Inc. has reduced its stake in CureVac N.V. by 22.1%, owning 267,404 shares valued at approximately $741,000 after selling 75,941 shares.
• A number of institutional investors have altered their positions in CureVac, with Greenleaf Trust and Two Sigma Advisers LP establishing new stakes during the first quarter of the year.
• Recent research reports have resulted in varying ratings for CureVac, with a consensus hold rating and a price target around $6.83, reflecting analysts' mixed views on the stock's performance.

Goldman Sachs Group Inc. reduced its position in CureVac N.V. (NASDAQ:CVAC - Free Report) by 22.1% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 267,404 shares of the company's stock after selling 75,941 shares during the period. Goldman Sachs Group Inc. owned 0.12% of CureVac worth $741,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CVAC. Greenleaf Trust purchased a new position in shares of CureVac in the first quarter worth about $31,000. Two Sigma Advisers LP bought a new position in CureVac in the 4th quarter worth approximately $48,000. Integrated Wealth Concepts LLC grew its stake in CureVac by 25.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock valued at $42,000 after buying an additional 3,000 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new stake in CureVac during the 4th quarter valued at $66,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of CureVac by 14.3% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company's stock worth $81,000 after acquiring an additional 3,648 shares in the last quarter. Institutional investors own 17.26% of the company's stock.

Wall Street Analyst Weigh In

CVAC has been the subject of several recent research reports. JMP Securities reiterated a "market outperform" rating and issued a $10.00 price target on shares of CureVac in a research report on Wednesday, May 28th. Citizens Jmp cut CureVac from a "strong-buy" rating to a "hold" rating in a research report on Thursday, June 12th. UBS Group lowered shares of CureVac from a "strong-buy" rating to a "neutral" rating and cut their price objective for the company from $12.00 to $5.50 in a research report on Thursday, June 26th. Jefferies Financial Group reaffirmed a "hold" rating and set a $5.00 price objective (down previously from $7.00) on shares of CureVac in a research note on Friday, June 13th. Finally, Citigroup cut shares of CureVac to a "market perform" rating in a research note on Thursday, June 12th. One research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $6.83.

CureVac Price Performance

CVAC opened at $5.36 on Wednesday. The stock's 50 day simple moving average is $5.41 and its 200 day simple moving average is $4.46. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.17 and a quick ratio of 6.16. CureVac N.V. has a 1 year low of $2.37 and a 1 year high of $5.72. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 5.58 and a beta of 2.53.

CureVac (NASDAQ:CVAC - Get Free Report) last announced its quarterly earnings data on Thursday, August 21st. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.15). CureVac had a net margin of 38.21% and a return on equity of 29.57%. The company had revenue of $1.41 million during the quarter, compared to the consensus estimate of $4.27 million. As a group, analysts predict that CureVac N.V. will post 0.72 earnings per share for the current year.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.